On July 18, 2019, the Board of Directors Cancer Genetics, Inc. accepted Dr. Michael J. Welsh’s resignation from his role as director and his membership on the compensation committee and his membership on the nominating committee of the Board. The resignation was not due to any disagreement on any matter relating to the Company’s operations, policies or practices. On July 8, 2019, the Board received a letter from John Pappajohn pursuant to which he resigned as a director of the Board, effective immediately. According to his resignation letter, and based on information known to the Company, Mr. Pappajohn’s decision to resign was due to his disagreement with the Company’s management regarding the Company’s entering into the Secured Creditor Asset Purchase Agreement, by and among the Company, Gentris, LLC, a wholly owned subsidiary of the Company, Partners for Growth IV, L.P., Interpace Diagnostics Group, Inc. and a newly-formed subsidiary of IDXG, Interpace BioPharma, Inc. and the transactions contemplated thereby.